Seeking Alpha
 

iShares Nasdaq Biotechnology ETF (IBB)

- NASDAQ
  • Nov. 19, 2014, 9:42 AM
    • Sylmar, CA-based Second Sight Medical Products (NASDAQ:EYES) debuts today via its IPO of 3.5M shares priced at $9.
    • The company develops visual prosthetics to restore some functional vision to blind patients. Its lead product is the Argus II System for the treatment of outer retinal degenerations such as retinitis pigmentosa. It is the only retinal prosthesis approved by the FDA and the first one approved anywhere in the world.
    • S-1
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | 2 Comments
  • Nov. 14, 2014, 1:46 PM
    • San Diego, CA-based Neothetics (NEOT) is set for its IPO of 4.3M shares of common stock at $13 - 15.
    • The clinical-stage specialty pharmaceutical firm develops therapeutics for the aesthetic market with an initial focus is on localized fat reduction and body contouring. Its lead product candidate is LIPO-202 (salmeterol xinafoate for injection) for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients (pot-belly). The company expects to conduct two Phase 3 trials in 1H 2015 and have top-line results by the end of 2015. If successful, it will file an NDA in 2H 2016.
    • 2013 Performance: Operating Expenses: $14.4M (+151.2%); Net Loss: ($15.0M) (-91.8%); Cash Burn: ($12.9M) (-74.3%).
    • 2014 Performance (9 mo.): Operating Expenses: $6.3M (-47.1%); Net Loss: ($7.9M) (+35.2%); Cash Burn: ($6.4M) (+40.2%).
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | 1 Comment
  • Nov. 14, 2014, 1:20 PM
    • New York, NY-base S1 Biopharma (Pending:SXB) is set for its IPO of 2.75M shares of common stock at $12 - 14.
    • The clinical stage biopharmaceutical firm develops therapies for sexual dysfunction. Its lead product candidate is Lorexys, a fixed-dose combination therapy for the treatment of female hypoactive sexual desire disorder (HSDD), currently in Phase 2 clinicals. Its second product candidate is Orexa for the treatment of male HSDD. The company expects to initiate a Phase 2a study in Q2 2015 and a Phase 2b trial in 2016.
    • 2013 Performance: Operating Expenses: $1.8M (-131.1%); Net Loss: ($2.0M) (-144.0%); Cash Burn: ($719K) (-628.3%).
    • 1H 2014 Performance: Operating Expenses: $1.6M (+74.5%); Net Loss: ($1.8M) (-93.3%); Cash Burn: ($838K) (-148.9%).
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Nov. 14, 2014, 12:00 PM
    • The money continues to flow out of biotech. The iShares NASDAQ Biotech Index (NASDAQ:IBB) is down 2%. The index is down almost 5% since the peak of 302.98 on October 31.
    • A sampling of moves today: (BIIB -4.3%)(CELG -3.4%)(AMGN -1.6%)(GILD -1.6%)(REGN -1.6%)(ALXN -2.3%)(VRTX -0.1%)
    | 41 Comments
  • Nov. 11, 2014, 2:06 PM
    • Raleigh, NC-based PRA Health Sciences (Pending:PRAH) is set for its IPO of 18.6M shares of common stock at $20 - 23.
    • The contract research organization provides clinical development services (Phases 1 - 4) to the biotech and pharmaceutical industries. Since 2000, the company has performed ~2,300 clinical trials.
    • KKR, one of the underwriters, acquired the firm in September, 2013 for $1.4B. KKR PRA Investors, L.P., will own ~64% of the stock after the IPO, ~59% if the underwriters' over-allotment is fully exercised.
    • The financials are difficult to compare due several transactions executed by KKR.
    • 2014 Performance (9 mo.) ($M): Revenues: 1,089.6 (+78.0%); Operating Income: 45.1 (+125.1%); Net Loss: (12.9) (+73.3%); CF Ops: 1.4 (-97.2%).
    • ETFs: IBB, BIB, IRY, BIS, IXJ, DRGS (NYSEARCA:IPO)
    | Comment!
  • Nov. 11, 2014, 1:38 PM
    • Rehovot, Israel-based NeuroDerm (NDRM) is on deck for its IPO of 4.5M shares of common stock at $13 - 16.
    • The clinical-stage pharmaceutical company focuses on reformulations of existing drugs targeted on central nervous system disorders. The reformulations are designed to overcome limitations such as short half-life and low absorption. It believes its regulatory approval pathways will be shorter and lower risk since they are based on already-approved medicines.
    • Its most advance product candidates target Parkinson's disease. Three Phase 3 trials are on tap for 2015.
    • 2013 Performance ($M): Operating Expenses/Loss: 3.2 (+15.8%); Net Loss: (86.9) (-999%).
    • 1H 2014 Performance ($M): Operating Expenses/Loss: 5.0 (-180.9%); Net Loss: 5.6 (+69.1%).
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Nov. 10, 2014, 1:46 PM
    • San Francisco, CA-based FibroGen (Pending:FGEN) is on deck for its IPO of 7.1M shares of common stock at $16 - 19.
    • The biopharmaceutical company focuses on fibrosis and hypoxia-inducible factor (HIF) biology. Its lead product is roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylases currently in Stage 3 development, for the treatment of anemia in patients with chronic kidney disease. Its second product candidate is FG-3019, a monoclonal antibody in Phase 2 development  for the treatment of idiopathic pulmonary fibrosis.
    • The company's development and commercialization partners for roxadustat are Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) (Japan, Europe, CIS, Middle East, South Africa) and AstraZeneca (AZN +0.6%) (U.S., China, ROW ex. Astellas territories).
    • 2013 Performance ($M): Revenues: 102.2 (+55.1%); Operating Expenses: 110.1 (+18.1%); Net Loss: (14.9) (+54.3%); CF Ops: 25.9 (+562.5%).
    • 2014 Performance (9 mo.): Revenues: 121.5 (+35.3%); Operating Expenses: 123.6 (+69.8%); Net Loss: (8.9) (-175.4%); CF Ops: 46.2 (-4.9%).
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Nov. 7, 2014, 11:57 AM
    • Jaguar Animal Health (NASDAQ:JAGX) postpones its IPO of 5M shares of common stock at $7 - 9. The company develops and commercializes gastrointestinal products for companion and production animals.
    • Parnell Pharmaceuticals' (NASDAQ:PARN) poor performance may have influenced its decision. The animal health products firm is down over 50% from its June IPO price of $10.
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Nov. 7, 2014, 11:46 AM
    • Chiropractic clinic operator The Joint Corp. (NASDAQ:JYNT) is set for its IPO of 3M shares of common stock at $9 - 11.
    • The company franchises chiropractic clinics on a non-insurance cash-based model. Patients do not need appointments since they are handled on a walk-in basis Its current network is 225 locations.
    • The company's value proposition is lower prices due to the elimination of the administrative costs of third party reimbursement and greater convenience due to longer operating hours and walk-in access. For the period 2010 - 2013, the company's clinics attracted an average of 540 - 948 new patients per year compared to the industry average of 364.
    • 2013 performance ($M): Revenues: 5.9 (+113.9%); Operating Expenses: 5.5 (+33.5%); Net Income: 0.2 (+121.2%).
    • 1H 2014 performance ($M): Revenues: 3.2 (+14.5%); Operating Expenses: 3.6 (+32.8%); Net Loss: (0.3) (-331.8%).
    • S-1
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Nov. 7, 2014, 11:03 AM
    • IPO medical device maker Nevro (NVRO -0.4%) holds on to yesterday's opening day pop. Shares are up 40% from the $18 offer price.
    • The company's product is the Senza spinal cord stimulation system for the treatment of chronic pain. It submitted its PMA to the FDA in June 2014 and expects to initiate the U.S. commercial launch by early 2016, if approved. Revenues since inception have been generated from Sensa sales in Europe and Australia.
    • Over 2,500 patients have received the device to date.
    • 2013 performance ($M): Revenues: 23.5 (+29.1%); Operating Expenses: 39.2 (+31.5%); Net Loss: (26.0) (-36.8%).
    • 1H 2014 performance ($M): Revenues:14.2 (+27.9%); Operating Expenses: 23.4 (+17.6%); Net Loss: (14.5) (-1.4%).
    • Prospectus
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Nov. 6, 2014, 1:59 PM
    • Biosimilar firm Coherus BioSciences (NASDAQ:CHRS) encounters less-than-expected investor interest in its first day of trading. Shares are off more than 5% from the $13.50 IPO price.
    • The late-clinical-stage biotech's lead product is an anti-TNF (tumor necrosis factor) biosimilar to Amgen's (AMGN +0.9%) Enbrel (etanercept) currently in Phase 3 development.
    • The company generates no revenue at present. Its net loss was $53.6M in 2013 and $50.1M in 1H 2014.
    • S-1
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | 2 Comments
  • Nov. 5, 2014, 1:42 PM
    • INC Research Holdings (Pending:INCR) is set for its IPO of 8,108,108 shares of common stock at $17 - 20.
    • The company is a contract research organization (CRO) that focuses on Phases 1 - 4 clinical development services for the biopharmaceutical and medical device industries. As of September 30, 2014 the firm employed 5,500 people in 50 countries across six continents.
    • 2013 performance ($M): Total Revenues: 995.1 (+14.6%); Net Service Revenues: 652.4 (+12.7%); Operating Income: 31.4 (+183.7%); Net Loss: (41.5) (+29.8%); Loss Per Share: ($0.81) (+28.9%); CF Ops: 37.3 (-13.3%).
    • 2014 (9 mo.) performance ($M): Total Revenues: 851.1 (+14.8%); Net Service Revenues: 596.0 (+24.7%); Operating Income: 45.2 (+123.8%); Net Income: 26.3 (+92.0%); EPS: 0.50 (+189.3%); CF Ops: 117.3 (+846.0%); Quick Assets (pro forma as adjusted): 106.0.
    • S-1
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Nov. 5, 2014, 1:12 PM
    • Xenon Pharmaceuticals' (NASDAQ:XENE) IPO of 4M shares of common stock at $9 debuted today. Initial interest is a bit tepid despite discounting the offer price from the original range of $10 - 12. Shares currently exchange hands at $9.69 (+7.7%) on turnover of only 455K.
    • Previously: Xenon Pharma on deck for IPO
    • ETFs: IBB, BIB, BIS (NYSEARCA:IPO)
    | Comment!
  • Oct. 26, 2014, 9:44 AM
    | 14 Comments
  • Oct. 21, 2014, 3:44 PM
    • Toronto-based clinical-stage biotech Aptose Biosciences will begin trading on the NASDAQ Capital Market on or about October 23 under the symbol "APTO."
    • The company's lead product is APTO-253 (KLF4 Activator) for the treatment of solid tumors and relapsed/refractory hematologic malignancies.
    • ETFs: IBB, BIB, BIS
    | Comment!
  • Oct. 20, 2014, 1:48 PM
    • Santa Barbara, CA-based Sientra (Pending:SIEN) is set for its IPO of 5M shares of common stock at $14 - 16.
    • The medical aesthetics company sells a variety of implants to plastic surgeons, including tissue expanders as well as body contouring and facial implants. Its primary products are silicone breast implants, offered in over 120 variations in size, shape and texture.
    • 2013 Operating Results ($M): Revenues: 35.2 (+238.5%); Gross Profit: 26.6 (+228.4%); Operating Expenses: 44.8 (+42.2%); Operating Loss: (18.2) (+22.2%); Net Loss: (19.1) (+18.4%); Cash Burn Ops: (25.9) (+13.1%).
    • 1H 2014 Operating Results ($M): Revenues: 21.9 (+22.3%); Gross Profit: 16.5 (+21.3%); Operating Expenses: 19.1 (-15.9%); Operating Loss: (2.6) (+71.7%); Net Loss: (1.2) (+87.5%); Quick Assets: 21.6 (pro forma as adjusted: 88.4); CF Ops: 2.2 (+119.0%).
    • S-1
    • ETFs: IBB, BIB, BIS (IPO +0.8%)
    | Comment!
Visit Seeking Alpha's
IBB vs. ETF Alternatives
IBB Description
The iShares Nasdaq Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index<sup>®</sup>.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub